Find clinical trials for Multiple Myeloma in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Multiple Myeloma trials near Paris, Île-de-France, FRA:
Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once ...
Phase 1
Villejuif Cedex, France and 3 other locations
be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patientsThis is an open-label, multicenter, no...
Phase 2
Paris, France and 28 other locations
of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...
Phase 2
Paris, France and 40 other locations
CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...
Phase 2
Paris 10, France and 35 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Paris, France and 59 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Paris, France and 139 other locations
This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma...
Phase 2
Paris, France and 19 other locations
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...
Phase 1
Paris, France and 39 other locations
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM r...
Phase 1
Villejuif Cedex, Val-de-Marne, France and 18 other locations
provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...
Phase 2
Paris Cedex 12, France and 72 other locations
Clinical trials
Research sites
Resources
Legal